ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.330
+0.090 (4.02%)
At close: Jan 9, 2026, 4:00 PM EST
2.360
+0.030 (1.29%)
After-hours: Jan 9, 2026, 7:59 PM EST
ImmunityBio Employees
ImmunityBio had 680 employees as of December 31, 2024. The number of employees increased by 52 or 8.28% compared to the previous year.
Employees
680
Change (1Y)
52
Growth (1Y)
8.28%
Revenue / Employee
$121,404
Profits / Employee
-$512,671
Market Cap
2.29B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 680 | 52 | 8.28% |
| Dec 31, 2023 | 628 | -97 | -13.38% |
| Dec 31, 2022 | 725 | 138 | 23.51% |
| Dec 31, 2021 | 587 | 322 | 121.51% |
| Dec 31, 2019 | 265 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IBRX News
- 12 days ago - ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025” - Business Wire
- 25 days ago - ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer - Business Wire
- 4 weeks ago - ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy - Benzinga
- 4 weeks ago - ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe - Business Wire
- 5 weeks ago - A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs - Seeking Alpha
- 7 weeks ago - ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech - Seeking Alpha
- 2 months ago - New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations - Business Wire
- 2 months ago - Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024 - Business Wire